Alpha 2.0
Login Register
» Authors » Junki Mizusawa

Junki Mizusawa

Explore the profile of Junki Mizusawa including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 172
Citations 4536
Followers 0
Related Specialties
Oncology
Gastroenterology
General Surgery
Top 10 Co-Authors
Haruhiko Fukuda
Hiroshi Katayama
Kenichi Nakamura
Masanori Terashima
Takaki Yoshikawa
Narikazu Boku
Mitsuru Sasako
Yukihide Kanemitsu
Takeshi Sano
Seiji Ito
Published In
Jpn J Clin Oncol
Gastric Cancer
Eur J Surg Oncol
Ann Gastroenterol Surg
Future Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Validation of the Japan Clinical Oncology Group postoperative complications criteria against CTCAE for evaluation of postoperative complications (JCOG1903A)
Sato Y, Mizusawa J, Katayama H, Doki Y, Takiguchi S, Kurokawa Y, et al.
Eur J Surg Oncol . 2025 Feb; 51(6):109669. PMID: 40009911
Introduction: The Common Terminology Criteria for Adverse Events (CTCAE) was originally used to evaluate surgical complications in clinical trials. However, there were some drawbacks, as CTCAE only evaluated the safety...
2.
Dose-finding and efficacy confirmation trial of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy for locally advanced maxillary sinus cancer (JCOG1212): final analysis
Shinomiya H, Matsuura K, Onimaru R, Ohkoshi A, Saito Y, Tachibana H, et al.
Int J Clin Oncol . 2025 Feb; 30(3):489-496. PMID: 39913014
Background: JCOG1212 is a dose-finding and efficacy confirmatory study of concurrent superselective intra-arterial infusion of cisplatin and radiotherapy (RADPLAT) for locally advanced primary squamous cell carcinoma of the maxillary sinus...
3.
Assessment of heterogeneity according to hospital or medical experience factors in outcomes of chemotherapy for advanced biliary tract cancer: a post-hoc analysis of JCOG1113
Fukushi K, Imaoka H, Ikeda M, Mizusawa J, Morizane C, Okusaka T, et al.
Jpn J Clin Oncol . 2025 Jan; PMID: 39775866
Background: JCOG1113 is a randomized phase III trial that showed non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in patients with advanced biliary tract cancer. Assessment of inter-institutional heterogeneity...
4.
Randomized controlled phase III study comparing chemotherapy alone versus conversion surgery after a remarkable response to chemotherapy in patients with initially unresectable cStage IVB or pStage IV gastric cancer (JCOG2301, Conversion study)
Kita R, Yasufuku I, Takahashi N, Mizusawa J, Sano Y, Fukuda H, et al.
Jpn J Clin Oncol . 2024 Dec; 55(3):304-310. PMID: 39690810
The standard approach for stage IV gastric cancer is palliative chemotherapy. However, despite the advancements in various chemotherapy regimens, the prognosis remains poor, highlighting the urgent need to develop more...
5.
Long-term follow-up of the conventional versus no-touch isolation technique for resection of primary colon cancer (JCOG1006): randomized clinical trial
Komori K, Takii Y, Mizusawa J, Kanemitsu Y, Shiozawa M, Ohue M, et al.
BJS Open . 2024 Nov; 8(6). PMID: 39602807
Background: The Japan Clinical Oncology Group (JCOG) 1006 was a phase III trial of patients with clinical T3/T4 colon cancer comparing the no-touch isolation technique ('No Touch') with the conventional...
6.
Sex differences in toxicities and survival outcomes among Japanese patients with Stage III colorectal cancer receiving adjuvant fluoropyrimidine monotherapy: A pooled analysis of 4 randomized controlled trials (JCOG2310A)
Hirano H, Kataoka K, Yamaguchi T, Wagner A, Shimada Y, Inomata M, et al.
Eur J Cancer . 2024 Nov; 214:115139. PMID: 39579641
Background: Fluoropyrimidine remains the key agent of adjuvant chemotherapy for stage III colorectal cancer (CRC). Western studies have shown that female sex is a favorable prognostic factor after surgery, but...
7.
Influence of major hepatectomy on gemcitabine-based chemotherapy for recurrent biliary tract cancer after surgery: a subgroup analysis of JCOG1113
Okuno T, Morizane C, Mizusawa J, Yanagimoto H, Kobayashi S, Imaoka H, et al.
Int J Clin Oncol . 2024 Oct; 30(1):83-91. PMID: 39441453
Background: Major hepatectomy (MH) can increase the risk of adverse events (AEs) owing to impaired drug metabolism due to decreased liver volume and surgical injury. Thus, we performed this subgroup...
8.
Consideration of factors of low accrual and methods for setting appropriate accrual periods: Japan Clinical Oncology Group study
Sasaki K, Mizusawa J, Bando H, Nakamura K, Kataoka T, Katayama H, et al.
Trials . 2024 Oct; 25(1):665. PMID: 39375801
Background: Poor patient accrual can delay reporting of clinical trials and, consequently, the development of new treatments. For reducing the risk of additional resource requirements, a method for setting planned...
9.
Factors influencing decision-making between surgery and chemoradiotherapy for esophageal carcinoma from the JCOG0502
Yamamoto S, Kato K, Daiko H, Ito Y, Kajiwara T, Kojima T, et al.
Future Oncol . 2024 Sep; 20(36):2849-2854. PMID: 39331122
Treatment options for esophageal squamous cell carcinoma includes surgery and chemoradiotherapy (CRT), however there was limited information about the factors influenced in patients' decision-making. Patients who participated in JCOG0502, a...
10.
Protocol digest of a phase III randomized trial of gross total resection versus possible resection of fluid-attenuated inversion recovery-hyperintense lesion on MRI for newly diagnosed supratentorial glioblastoma: JCOG2209 (FLAMINGO)
Sekino Y, Sonoda Y, Shibahara I, Mizusawa J, Sasaki K, Sekita T, et al.
Jpn J Clin Oncol . 2024 Sep; 55(1):75-79. PMID: 39292165
The goal of surgery for patients with newly diagnosed glioblastoma (GBM) is maximum safe resection of the contrast-enhancing (CE) lesion on magnetic resonance imaging. However, there is no consensus on...